Competitor Analysis: Anti-Infective Antibodies

Published by: La Merie Publishing

Published: Jul. 1, 2010 - 136 Pages


Table of Contents


Index

Recombinant Antibodies for Viral Diseases


Respiratory Syncytial Virus (RSV)

Human Immune Deficiency Virus (HIV)

Hepatitis C Virus (HCV)

Rabies Virus

Influenza Virus

Herpes Simplex Virus

Hemorrhagic Fever Viruses

Vaccinia Virus

Cytomegalovirus (CMV)

Various Viruses

Unspecified Virus, Broad Spectrum Antiviral Antibodies


Recombinant Antibodies for Bacterial Diseases


Bacillus Anthracis

Staphylococci

Pseudomonas

Streptococci

Clostridium Difficile

Clostridium Botulinum

Various Bacteria

Unspecified Bacteria, Broad Spectrum Antibacterial Antibodies

Recombinant Antibodies for Fungal Diseases


Recombinant Antibodies for Parasitic Diseases


Human Plasma-Derived Immunoglobulins


Conventional Intravenous Immunoglobulins (IVIG)

Modern Intravenous Immunoglobulins

Enriched Immunoglobulins

Injectable SC/IM Immunoglobulins

Oral Immunoglobulins

Specific Immunoglobulins (Hyperimmunes)


Varicella Zoster Immunoglobulins (VZIG)

Tetanus Immunoglobulins

Rabies Immunoglobulins

Hepatitis B Immunoglobulins

Hepatitis A Immunoglobulins

Cytomegalovirus Immunoglobulins

Vaccinia Immunoglobulins

Various Immunoglobulins


Licensing & Collaboration Agreements Anti-Infective Antibodies


Corporate Anti-Infective Antibody Portfolios and R&D Pipelines


About Competitor Analysis Series:

Abstract

The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and human plasma-derived immunoglobulins and hyperimmunes for post-exposure prophylaxis and treatment of infectious diseases as of July 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The emergence of antibiotic resistant microorganisms, lethal viruses and the threat of engineered microorganism have newly stimulated the interest in recombinant antibodies for infectious diseases. Advances in understanding pathogenetic mechanisms and new antibody technologies have further contributed to a growing class of anti-infective antibodies. Apart from recombinant mono- or polyclonal antibodies, human plasma-derived immunoglobulins have their place in the treatment of immunedeficiencies and specific immunoglobulins (hyperimmunes) are part of standard protocols in post-exposure prophylaxis of a number of infectious diseases. Modern plasma-derived immunoglobulins are characterized by improved purification procedures, more convenience (room temperature stable, ready-to-use preparations, new stabilizers, higher concentrated) and new developments.

The report includes a compilation of product portfolios and current active projects in research and development of anti-infective antibodies and immunoglobulins. In addition, the report lists company-specific R&D pipelines product portfolios anti-infective antibodies, immunoglobulins and hyperimmunes. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.